Tissue Doppler and Strain Rate Imaging Detect Improvement of Myocardial Function in Iron Deficient Patients with Congestive Heart Failure after Iron Replacement Therapy

Gaber, Rania; Kotb, Nesreen A; Ghazy, Medhat; Nagy, Hala; Salama, Mai; Elhendy, Abdou

doi:10.1111/j.1540-8175.2011.01532.x

Cited by 55 publications

(76 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results suggest that iron treatment does have a large effect on both sFe (Hedges’ g=0.966, p<0.001; figure 4) and Tsat (Hedges’ g=0.730, p<0.001; figure 3). However, this finding should be interpreted with caution if one intends is to use these measures to indicate iron status or a positive response to treatment because some individual studies showed no change after treatment 15 19 25 27 28 31 34 35 39 41. The treatment failure common to these studies suggests that the IDNA was not severe enough for an intervention to impact iron status.…”

Section: Discussionmentioning

confidence: 94%

Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Cardiac magnetic resonance imaging studies show that low myocardial iron (as measured by myocardial T2* imaging) was associated with non-ischaemic heart failure (Nagao et al, 2014(Nagao et al, , 2015 While there may be multiple pathways through which iron deficiency can impair cardiac function, tissue Doppler and strain rate measurements show significant improvements in diastolic and systolic myocardial function in iron-deficient patients after iron replacement therapy (Gaber et al, 2012).…”

Section: Pathophysiology Of Iron Deficiency In the Failing Heartmentioning

confidence: 99%

Investigation and treatment for iron deficiency in heart failure: the unmet need in Lower and Middle Income Countries

Makubi

Roberts

2017

Br J Haematol

View full text Add to dashboard Cite

Summary Frank iron deficiency has been associated with a wide range of cardiac and pulmonary abnormalities including non‐ischaemic cardiomyopathy. Iron deficiency anaemia and isolated iron deficiency are well‐defined adverse prognostic factors in non‐ischaemic cardiac failure. Furthermore, iron‐deficient patients in chronic heart failure with a serum ferritin of <100 μg/l or <300 μg/l with reduced transferrin saturation of <20%, who were given intravenous iron showed improved clinical outcomes. Iron deficiency with or without anaemia affects over a quarter of the world's population, but the impact of iron deficiency in heart failure and the effective management of iron deficiency in heart failure in Lower and Middle Income Countries (LMICs) is not well described. Heart failure in African cohorts occurs at a younger age than in North America and Europe and is more likely to be due to hypertension. Recent studies suggest that iron deficiency anaemia, which is very common in heart failure patients in Africa, and iron deficiency are independently associated with a poor prognosis in heart failure. Preliminary data suggest that iron deficiency in patients with heart failure can be treated with oral iron, with significant beneficial effects on haematological and physiological variables. Cost may prohibit the use of intravenous iron on a large scale in LMICs and optimal regimes to treat iron deficiency in heart failure patients with oral iron therapy remain to be defined.

show abstract

“…Gaber et al , found that correction of iron deficiency improves functional class and walking distance in non-anemic iron deficient patients with systolic HF. 24 They also found significant improvement of diastolic and systolic function using echocardiogram after therapy despite lack of improvement of LVEF. 24 Ongoing clinical trials are addressing the role of iron supplementation in both anemic and non-anemic patients with HF.…”

Section: Discussionmentioning

confidence: 92%

Usefulness of Relative Hypochromia in Risk Stratification for Nonanemic Patients With Chronic Heart Failure

Hammadah

Brennan

et al. 2016

The American Journal of Cardiology

View full text Add to dashboard Cite

The purpose of this study is to investigate the impact of a reduction of hemoglobin (Hb) content in the erythrocytes as estimated by mean corpuscular hemoglobin concentration (MCHC) on long-term clinical outcomes in non-anemic patients with heart failure (HF). We prospectively enrolled 1,579 subjects with HF undergoing coronary angiography enrolled in the GeneBank study with 5-year follow-up of all-cause mortality. Levels of Hb and MCHC were assessed at enrollment and after 6 months of follow up. Anemia was defined as Hb levels <13 g/dL in males, and <12 g/dL in females. In our non-anemic cohort (n=785, 49.7%), mean Hb and median MCHC were 13.8±1.1 g/dL and 34.3 (interquartile range 33.6-35) g/dL, respectively. Non-anemic HF patients with lower MCHC had higher mortality risk (Quartiles 1 vs 4, Hazard ratio = 2.1, 95% confidence interval 1.4-3.3, p=0.001). In a subset of non-anemic patients with persistent normal Hb on follow-up (n=206), the mean time between baseline and follow up MCHC levels was 169.3±41.6 days. In comparison to patients with levels of MCHC above the first quartile (≥33.6 g/dL) on baseline and follow up, patients with persistently low MCHC (<33.6 g/dL) had a significantly increased mortality risk (log rank <0.001). All models remained significant even after adjusting for traditional cardiac risk factors, left ventricular ejection fraction, baseline Hb levels and mean corpuscular volume. In conclusion, relative hypochromia is an independent predictor of increased mortality risk in patients with HF, even in the setting of normal Hb levels.

show abstract

Tissue Doppler and Strain Rate Imaging Detect Improvement of Myocardial Function in Iron Deficient Patients with Congestive Heart Failure after Iron Replacement Therapy

Cited by 55 publications

References 30 publications

Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis

Is iron treatment beneficial in, iron-deficient but non-anaemic (IDNA) endurance athletes? A systematic review and meta-analysis

Investigation and treatment for iron deficiency in heart failure: the unmet need in Lower and Middle Income Countries

Usefulness of Relative Hypochromia in Risk Stratification for Nonanemic Patients With Chronic Heart Failure

Contact Info

Product

Resources

About